Business Context and Reporting Period
This Form 8-K Current Report was filed by Lifemd, Inc. on March 21, 2023. The filing discloses the entry into a material definitive agreement involving a new senior secured credit facility.
Key Financial Metrics and Transaction Details
- Credit Facility Size: Up to $40 million aggregate principal amount.
- Initial Advance: $15 million drawn on March 21, 2023.
- Future Commitments: Up to $5 million committed for Q4 2023; up to $20 million available at lender discretion during the term.
- Interest Rate: Variable rate equal to the greater of (i) 4.75% plus the Prime Rate or (ii) 12.50% per annum.
- Repayment Terms: Interest-only payments for up to 24 months, followed by full amortization.
- Maturity Date: October 1, 2026.
- Upfront Costs: $200,000 commitment fee (1.00% of the $20 million commitment).
- Equity Components: Issuance of warrants to purchase $1.2 million of common stock; lenders may convert up to $2 million of the initial advance into common stock at 120% of the Stock Purchase Price.
Material Changes and Covenants
The filing represents a significant change in the company's capital structure through the addition of senior secured debt. The company is now subject to specific financial covenants:
- Liquidity Covenant: Must maintain at least $5 million of unrestricted cash, tested monthly starting from the closing date.
- Cash Flow Covenant: Must maintain a trailing six-month cash flow of at least $2 million, tested quarterly starting with the period ended September 30, 2023.
- Prepayment Penalty: Ranges from 1.00% to 3.00% of the principal amount prepaid, depending on timing.
Outlook, Risks, and Contingencies
The transaction provides immediate liquidity and potential future funding, subject to lender discretion for the remaining $20 million. Key risks include:
- Events of Default: Acceleration of debt obligations may occur due to payment failures, material adverse effects, defaults on liabilities exceeding $500,000, or covenant breaches.
- Dilution Risk: Potential conversion of $2 million of debt and exercise of warrants could dilute existing shareholders.
- Interest Rate Exposure: The variable interest rate exposes the company to fluctuations in the Prime Rate, with a floor of 12.50%.
Investor Verification Checklist
- Verify the company's current unrestricted cash balance against the $5 million monthly covenant requirement.
- Review the full text of the Loan Agreement (Exhibit 10.1) for detailed definitions of "Material Adverse Effect" and other default triggers.
- Monitor the company's ability to meet the $2 million trailing six-month cash flow covenant starting in Q4 2023.
- Assess the potential dilution impact of the $1.2 million warrant issuance and the $2 million convertible debt feature.
- Confirm the status of the $5 million Q4 2023 commitment and the conditions required to access the discretionary $20 million.